Background Multiple sclerosis (MS) therapeutic goals have traditionally been dichotomized
into two distinct avenues: immune-modulatory-centric interventions and pro-regenerative …

Intrathecal synthesis of central nervous system (CNS)-reactive autoantibodies is observed
across patients with autoimmune encephalitis (AE), who show multiple residual …

Multiple Sclerosis (MS) is an inflammatory, demyelinating, and neurodegenerative disease
of the central nervous system (CNS) and is termed as one of the most common causes of …

Background Multiple sclerosis (MS) is a neuroinflammatory disease triggered by a
combination of genetic traits and external factors. Autoimmune nature of MS is proven by the …

Optimizing the design of nanoparticulate co-delivery systems of antigens and
immunomodulators to induce antigen-specific immune tolerance effectively remains a …

Primary progressive multiple sclerosis (PPMS), the least frequent type of multiple sclerosis
(MS), is characterized by a specific course and clinical symptoms, and it is associated with a …

Introduction Cladribine is a deoxyadenosine analogue that can penetrate the blood–brain
barrier. It is used to treat multiple sclerosis (MS). However, the mechanistic understanding of …

Exhilarating breakthroughs in the treatment of autoimmune diseases through antigen-
specific therapies offer new hope for patients. Herein, a novel antigen-specific reverse …

The diagnosis and quantification of Multiple Sclerosis (MS) have typically depended on
skilled doctors recognizing visual patterns, such as Magnetic Resonance Imaging (MRI) and …

distinctive IgG-mediated pathogenesis for primary progressive multiple sclerosis? | Brain |
Oxford Academic Skip to Main Content Advertisement Oxford Academic Journals Books Search …